Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05123963
Other study ID # MP-31-2021-4011
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 15, 2021
Est. completion date April 30, 2025

Study information

Verified date May 2024
Source Université de Sherbrooke
Contact Frédérique Frisch
Phone 819-346-1110
Email frederique.frisch@usherbrooke.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed, a preliminary study in humans revealed that afternoon high-intensity interval training (HIIT) exercise was more effective than morning exercise in improving 24h blood glucose levels in men with T2D. Another recent study in mice showed that the time of day is a critical factor in augmenting the beneficial effects of exercise on the skeletal muscle metabolome as well as on whole-body energy homeostasis. However, human studies that specifically target the impact of timing of exercise training on glucose homeostasis and metabolic health are scarce and the potential underlying mechanisms largely unknown. The overarching goals of this project is to improve 24-hour rhythmicity of metabolism in men and women with prediabtes by appropriate timing of exercise and to assess its effect on metabolic health and immune response. Acute and prolonged exercise interventions timed in the morning vs late afternoon will be carried out in individuals with prediabetes to determine whether acute exercise in the afternoon and prolonged exercise training in the afternoon can improve peripheral insulin sensitivity, compared to exercise in the morning, and positively affect adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles.


Description:

Three metabolic studies A, B and C using PET imaging will be carried out at the CRCHUS. The 12-week exercise training intervention will consist of supervised cycling high-intensity interval training (i.e. short bouts of high-intensity exercise interspersed with short periods of rest) every other day at the CRCHUS. Continuous glucose monitoring will be used to measure 24h glucose profiles over 3-4 days prior to and following the acute exercise bout and again during the last week of the intervention. Continuous blood pressure monitoring will be used over 18-24 h, at the beginning and at the end of the 12 week-training. Participants will take part in three postprandial metabolic studies: 1) before (A); 2) 18-24h after an acute exercise bout (B), and; 3) after 12-weeks of exercise training (C). Experiments will be conducted between 07:30 AM and 5:00 PM, following a 12 hr fast. Adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles will be measured by the oral [18F-]-FTHA PET method. Changes in lean tissue mitochondrial function in vivo will be determined using magnetic resonance spectroscopy (MRS). Participants will complete Visit A (baseline), followed 7 to 14-days later by a pre-breakfast (9 AM) or pre-dinner (4PM) exhaustive glycogen lowering exercise bout. The following day (18-24h after the exercise bout), participants will return for a second metabolic visit (Visit B). Participants will then begin a 12-week supervised high-intensity interval training program, performed either only in the morning or only in the afternoon (9 AM vs. 4 PM), on every other day. At the end of the 12 weeks, and at least 48h after the last exercise bout, participants will return for their final metabolic visit (Visit C).


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date April 30, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Pre-diabetes: - Fasting plasma glucose: 6.1 to 6.9 mmol/L or - 2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol/L and - HbA1c: 6.0 to 6.4% - or Insulin resistant: glucose clearance rate = 360 ml/kg/min as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min. - BMI > 25 kg/m2 - To be willing and able to adhere to the specifications of the protocol; - To have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and were willing to participate in the study. Exclusion Criteria: - overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG - Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies); - presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder; - Uncontrolled severe hypertension, systolic pressure = 180 mm Hg or diastolic pressure = 110 mm Hg; - History of ischemic heart disease, tachyarrhythmia, QT interval prolongation, risk factors for torsade de pointes (eg hypokalemia), or taking any medication known to prolong the QT interval; - History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux requiring surgery, etc.); - Presence of a pacemaker; - Having undergone a PET study or CT scan in the past year; - Any contraindication to stopping statins for 3 months and stopping an anti-hypertensive medication and metformin for 7 days; - smoking (>1 cigarette/day) and/or consumption of >2 alcoholic beverages per day; - No blood donation two month prior the study; - prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting TG > 6 mmol/l.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High-intensity interval training
3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.

Locations

Country Name City State
Canada Centre de recherche du CHUS Sherbrooke Quebec

Sponsors (9)

Lead Sponsor Collaborator
Université de Sherbrooke Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Laval University, Leiden University Medical Center, Maastricht University Medical Center, McMaster University, University of Calgary, University of Waterloo, Wageningen University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Adipose tissue dietary fatty acid (DFA) partitioning Determined using oral administration of [18F]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Primary Change in lean organ (heart, liver, skeletal muscle) DFA partitioning Determined using oral administration of [18F]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Primary Change in skeletal muscle ATP fluxes in vivo Determined using phosphorus-31 magnetic resonance spectroscopy. Measured 170 minutes before and 30 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Primary Change in glucose control. Determined using continuous glucose monitoring and repeated blood samples obtained during metabolic visit. Measured continuously 2-3 days before and 2-3 days after first and final exercise session, after 12-week exercise intervention.
Secondary Change in adipose tissue nonesterified fatty acid (NEFA) metabolism. Determined using [11C]-palmitate with dynamic PET acquisition Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in lean organ (heart, liver, skeletal muscle) NEFA metabolism. Determined using [11C]-palmitate with dynamic PET acquisition Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in insulin sensitivity Determined by measuring circulating glucose, NEFA, insulin and C-peptide following the liquid meal. Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in dietary fatty acid oxidation Determined by measuring breath [13C]-carbon dioxide enrichment. Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in total substrate utilisation Determined using indirect calorimetry Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in postprandial plasma NEFA turnover. Determined using continuous infusion of [7,7,8,8-2H]-palmitate. Blood sample collected every 60 min following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in postprandial plasma glucose turnover Determined using continuous infusion of [1-3H]-glucose Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in left ventricular function by Positron Emitting Positron (PET) ventriculography Determined using [11C]-palmitate combined with ECG-gated cardiac dynamic PET acquisition. Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in plasma distribution of DFA metabolites Determined using oral administration of [18F]-FTHA to quantify the incorporation of 18F-labeled fatty acids given with the liquid meal, into triglyceride-rich lipoproteins and NEFA. Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in composition and activation status of immune cell subsets Determined by extensive Fluorescence Activated cell Sorting (FACS) analysis Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
Secondary Change in plasma cytokine levels Determined by ELISA Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
See also
  Status Clinical Trial Phase
Completed NCT05424107 - A Mediterranean Intervention on Prediabetic Children N/A
Recruiting NCT02681887 - Effect of Melatonin on Cardiometabolic Risk- FULL Phase 3
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Recruiting NCT02561377 - Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics) N/A
Completed NCT02678390 - Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes N/A
Completed NCT02551640 - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients N/A
Completed NCT02459691 - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos) N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Completed NCT01479933 - Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes N/A
Completed NCT00960973 - The Effect of Vitamin K Supplementation on Glucose Metabolism Phase 4
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Recruiting NCT05340868 - Genetics of the Acute Response to Oral Semaglutide N/A
Recruiting NCT04984421 - IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE) N/A
Recruiting NCT04131582 - Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes Phase 3
Recruiting NCT04134650 - Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes Phase 3
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Completed NCT04074148 - Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Completed NCT02684565 - Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects N/A
Completed NCT01956929 - Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism. Phase 1